Welcome to our dedicated page for Burning Rock Biotech American Depositary Shares news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech American Depositary Shares stock.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is a pioneering cancer diagnostics company headquartered in China, established in 2014. The company is dedicated to leveraging next-generation sequencing (NGS) technology to advance precision oncology. This innovative approach aids in the selection of cancer therapies and the early detection of cancer, enhancing treatment outcomes and patient care.
Burning Rock operates through three primary segments: Central laboratory business, In-hospital business, and Pharma research and development services. The central laboratory business generates the majority of the company’s revenue. The company’s suite of products includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, which provide comprehensive cancer profiling and support personalized treatment plans.
In a strategic move to comply with NASDAQ Listing Rules 5810(c)(3)(A), Burning Rock must meet the minimum bid price requirement by June 26, 2024. Should the company's ADSs maintain a closing bid price of at least US$1.00 for ten consecutive business days, NASDAQ will confirm compliance, closing the matter. Failing this, the company might be granted an additional 180-day period to meet the requirement.
Recently, Burning Rock announced an ADS Ratio Change, equivalent to a one-for-ten reverse ADS split, effective immediately. Certificate holders must surrender existing ADSs for the new ratio, while uncertificated ADSs will auto-adjust. This change is expected to proportionally increase the ADS price, although no guarantees are provided.
Burning Rock’s mission, “Guard Life via Science,” underscores its commitment to advancing cancer diagnostics and treatment through scientific innovation. The company continues to make significant strides in cancer early detection, moving beyond proof-of-concept R&D into clinical validation.
For more information, visit ir.brbiotech.com.
Burning Rock Biotech (NASDAQ: BNR, LSE: BNR) will change the ratio of its American Depositary Shares (ADS) to Class A ordinary shares, effective May 15, 2024. The new ratio will be one ADS representing ten Class A shares, akin to a one-for-ten reverse ADS split. Certificates must be exchanged through Citibank for new ADSs, while uncertificated ADSs will be automatically adjusted. Trading on NASDAQ and LSE will continue under the symbol 'BNR' with updated security codes. Fractional new ADSs won't be issued; instead, they will be sold, and proceeds distributed to holders. The ADS price is anticipated to rise tenfold, although no guarantee is provided.
Burning Rock Biotech (BNR), a precision oncology company, published its 2023 Annual Report on Form 20-F, filing it with the SEC. The report is accessible on the SEC and company websites, highlighting financial and operational performance.
FAQ
What is the current stock price of Burning Rock Biotech American Depositary Shares (BNR)?
What is the market cap of Burning Rock Biotech American Depositary Shares (BNR)?
What is Burning Rock Biotech Limited?
What are the main business segments of Burning Rock?
How does Burning Rock generate most of its revenue?
What recent compliance measure did Burning Rock announce?
What is the ADS Ratio Change for Burning Rock?
What products does Burning Rock offer?
What is the mission of Burning Rock Biotech Limited?
Where can I find more information about Burning Rock?
What does the ADS ratio change mean for investors?
Are there any changes to Burning Rock's Class A ordinary shares?
